Valneva SE 2018 AR2
The report highlights Valneva's financial and operational achievements in 2018, including exceeding ‐100 million in product sales and raising ‐50 million to accelerate key vaccine development programs. The company made significant clinical progress with its vaccine candidates for Lyme disease, chikungunya, and Zika. Valneva's corporate social responsibility approach is structured around four pillars: protecting lives, acting ethically, developing people, and respecting the environment. Additionally, the company continued its support for the United Nations Global Compact and local community initiatives, such as the Baan Dek Foundation.
Company: Valneva SE
Sector: Health Care
Country: France
Year: 2018
Type: AR2
Pages: 48
Back to company
Valneva SE
Annual Business Report
The report highlights Valneva's financial and operational achievements in 2018, including exceeding ‐100 million in product sales and raising ‐50 million to accelerate key vaccine development programs. The company made significant clinical progress with its vaccine candidates for Lyme disease, chikungunya, and Zika. Valneva's corporate social responsibility approach is structured around four pillars: protecting lives, acting ethically, developing people, and respecting the environment. Additionally, the company continued its support for the United Nations Global Compact and local community initiatives, such as the Baan Dek Foundation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees